Printer Friendly

VIRAL TESTING SYSTEMS' JANUARY SALES OF HIV TEST BETTER THAN EXPECTED

 HOUSTON, Jan. 26 /PRNewswire/ -- Viral Testing Systems (AMEX: VTS) announced today that January sales of the FLUOROGNOST HIV-1 IFA test will approach or possibly exceed $200,000, according to Paul Montle, VTS president. Montle said this represents a 300 percent increase since September when VTS logged about $50,000 in FLUOROGNOST sales. VTS began marketing the HIV test in July of 1992.
 "These numbers are better than I had expected by this time. A few months ago, we stated that our average monthly sales target would be $600,000 by the end of 1993. I really did not expect us to be at $200,000 until March or April. Needless to say, FLUOROGNOST is garnering rapid acceptance and with notable institutions; we will begin announcing some FLUOROGNOST users over the next several weeks," said Montle.
 FLUOROGNOST is the only FDA-approved HIV test that holds a dual license for both screening and confirming, and can do so within 90 minutes. In a February memorandum from the FDA, blood banks and plasma centers were notified regarding FLUOROGNOST's approval and inherent ability to resolve Western Blot's indeterminate samples for medical counseling purposes. Indeterminate Western Blot results can range from 15 percent to 30 percent. VTS owns the North American licensing, marketing, and distribution rights to FLUOROGNOST.
 Enhancing future revenue prospects from FLUOROGNOST sales is that VTS filed an IND application with the FDA for its HIV-2 IFA on Jan. 4, 1993. The HIV-2 confirmation test has assumed greater importance due to the fact that the blood supply is now being screened for the HIV-2 virus. FLUOROGNOST HIV-2 IFA holds great promise since currently there is no FDA-approved confirmation test available. VTS expects FDA approval on its HIV-2 IND application by the end of February, at which time clinical trials will begin.
 Until recently, most of VTS FLUOROGNOST sales had been to laboratories and health institutions for evaluation purposes. "Now, we have begun to reach critical mass," Montle stated. "The bulk of our sales are coming from industry leaders. The really good news is that most of our sales have been from re-orders for confirmation testing purposes. We're very excited."
 -0- 1/26/93
 /CONTACT: Holly Vaughan of Viral Testing Systems Corporation, 713-228-1544/
 (VTS)


CO: Viral Testing Systems ST: Texas IN: MTC SU:

CK-OS -- NY054 -- 9065 01/26/93 12:14 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 26, 1993
Words:388
Previous Article:TCF BANK TO REDEEM SUBORDINATED CAPITAL NOTES
Next Article:"BIG BIRD TO FLY AGAIN"; KFC TO REBUILD BIG CHICKEN
Topics:


Related Articles
VIRAL TESTING SYSTEMS ANNOUNCES THAT THE FDA CLEARS IND FOR ITS HIV-2 AIDS CONFIRMATION TEST
TRAVIS PARTNERS EXERCISES VIRAL TESTING SYSTEMS CORPORATION WARRANTS
VIRAL TESTING SYSTEMS ANNOUNCES SALE OF ITS TELEPHONE BUSINESS
NEW AIDS SCREENING TEST DETECTS VIRUS EARLIER; NOW AVAILABLE TO BLOOD AND PLASMA COLLECTION CENTERS
FDA ADVISORY COMMITTEE RECOMMENDS APPROVAL FOR ROCHE'S AMPLICOR HIV MONITOR TEST
FDA ADVISORY COMMITTEE RECOMMENDS APPROVAL FOR ROCHE'S AMPLICOR HIV MONITOR TEST
AMPLICOR HIV-1 MONITOR(TM) TEST FIRST TO RECEIVE FDA APPROVAL FOR MARKETING
Phase One Clinical Studies Completed on Simplex Rapid HIV Saliva Test
Rapid replication ID.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters